Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Regeneron (REGN) Stock Price & Analysis
3,929 Followers
REGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$684.81 - $998.33
Previous Close$883.2
Volume369.92K
Average Volume (3M)467.12K
Market Cap
$97.32B
Enterprise Value$89.17B
Total Cash (Recent Filing)$10.84B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)25.4
Beta0.66
Next Earnings
May 02, 2024EPS Estimate
$10.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)34.75
Shares Outstanding109,761,896
10 Day Avg. Volume455,673
30 Day Avg. Volume467,116
Standard Deviation0.09
R-Squared0.00440
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.89
Price to Sales (P/S)7.34
Price to Cash Flow (P/CF)22.20
P/FCF Ratio28.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.80
Enterprise Value/Gross Profit7.32
Enterprise Value/Ebitda19.00
Forecast
1Y Price Target
$1,044.33Price Target Upside17.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Regeneron News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyRinvoq showed superior Week 16 efficacy over Dupi in a head-to-head atopic dermatitis study.
Market DemandOverall demand dynamics continue to remain strong with robust growth across all regions.
Product LaunchThe April 1 permanent J-code for Eylea HD is expected to be very important to the success of the launch, as it will likely encourage more prescribers to adopt the drug.
Bears Say
Legal IssuesThe US Department of Justice filed a False Claims Act Complaint against REGN regarding Eylea Medicare drug pricing, potentially costing the Medicare system hundreds of millions of dollars.
Market CompetitionTezepelumab Ph2 showed a modest exacerbation rate reduction, less compared to Dupilumab's rate reduction in similar trials, casting doubts on its competitive edge in the market.
Regulatory ChallengesThe FDA issued a CRL for Regeneron's odronextamab due to misalignment on confirmatory studies, indicating challenges with the drug's approval process.
---
Ownership Overview
3.04% Insiders
34.04% Mutual Funds
24.36% Other Institutional Investors
38.55% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $684.80 and its highest was $998.33 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is May 02, 2024 which is tomorrow.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Feb 02, 2024. The company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.731 by $1.129.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is $10.18.
How many shares outstanding does Regeneron have?
Regeneron has 108,367,355 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.86 in its last earnings report, beating expectations of $10.731. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,044.33 (17.01% Upside)
$1,044.33 (17.01% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 119.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $32.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.31%
12-Months-Change
Fundamentals
Return on Equity
16.26%
Trailing 12-Months
Asset Growth
13.18%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q4 2024
0:00 / 0:00
---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Months Forecast
Average Price Target
$1,044.33
▲(17.01% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
22/29 ratings generated profit
1 Year Average Return
+11.88%
reiterated a buy rating 2 months ago
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 75.86% of your transactions generating a profit, with an average return of +11.88% per trade.
---